Ayush Shukla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ayush Shukla has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Akhil Sharma
King George's Medical University, Lucknow, Uttar Pradesh, 226003, India
3 shared publications - Sharad Chandra
King George's Medical University, Lucknow, Uttar Pradesh, 226003, India
3 shared publications Abhishek Singh
Department of Cardiology, King George’s Medical University
2 shared publicationsAkshyaya Pradhan
Department of Cardiology, King George’s Medical University
2 shared publications- Akshyaya Pradhan
Department of Cardiology, King George’s Medical University, Lucknow, India
2 shared publications - Anil Kumar Tripathi
Department of Clinical Hematology and Medical Oncology, King George's Medical University, Lucknow 226003, Uttar Pradesh, India
2 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1899340
Comparison of no-reflow phenomenon in patients with ST-segment- elevation myocardial infarction undergoing primary PCI vs. pharmaco-invasive strategy: a single-centre study
Background: The no-reflow phenomenon after percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) represents a major barrier to successful reperfusion, leading to adverse outcomes despite epicardial vessel patency. Comparative evidence regarding its incidence and clinical consequences between primary PCI and pharmaco-invasive PCI remains scarce. Aim: The study aimed to compare the incidence of the no-reflow phenomenon in patients undergoing pharmaco-invasive PCI versus primary PCI, and to evaluate the short-term clinical outcomes of patients with no-reflow at three months post-procedure. Methods: In this prospective, single centre, observational study, STEMI patients presenting within 24 h of symptom onset were enrolled at a tertiary care centre. Patients experiencing no-reflow were categorized into Group A (primary PCI; n = 92) and Group B (pharmaco-invasive PCI; n = 192). Baseline demographics, comorbidities, angiographic characteristics, and outcomes were analysed. The primary outcome was the incidence of major adverse cardiac events at three months. Results: Among 857 patients undergoing primary PCI and 2,976 undergoing pharmaco-invasive PCI, the incidence of no-reflow was significantly higher in the primary PCI group (10.7% vs. 6.5%). Patients in Group A were older (58.9 ± 13.6 vs. 54.4 ± 11.4 years; P = 0.004) and more frequently diabetic (55.4% vs. 41.6%; P = 0.029), whereas hypertension was more prevalent in Group B (42.7% vs. 13.0%; P < 0.001). Baseline TIMI 0 flow was more common in Group A (79.3% vs. 24.5%; P < 0.001). After PCI, final TIMI 3 flow rates were comparable (85.9% vs. 89.6%; P = 0.361). In-hospital complications and three-month outcomes were similar between two groups: death (4.3% vs. 5.2%), revascularization (4.3% vs. 4.7%), and rehospitalization (5.4% vs. 3.1%) (all P > 0.05). Conclusion: No-reflow was more frequent after primary PCI, particularly in older, diabetic, and late-presenting patients with baseline TIMI 0 flow. Both reperfusion strategies achieved comparable short-term clinical outcomes in no-reflow patients. Pharmaco-invasive PCI may mitigate the risk of no-reflow in selected STEMI patients while maintaining equivalent early prognosis.
- 13 August 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1899340
Open AccessComparison of no-reflow phenomenon in patients with ST-segment- elevation myocardial infarction undergoing primary PCI vs. pharmaco-invasive strategy: a single-centre study
Background: The no-reflow phenomenon after percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) represents a major barrier to successful reperfusion, leading to adverse outcomes despite epicardial vessel patency. Comparative evidence regarding its incidence and clinical consequences between primary PCI and pharmaco-invasive PCI remains scarce. Aim: The study aimed to compare the incidence of the no-reflow phenomenon in patients undergoing pharmaco-invasive PCI versus primary PCI, and to evaluate the short-term clinical outcomes of patients with no-reflow at three months post-procedure. Methods: In this prospective, single centre, observational study, STEMI patients presenting within 24 h of symptom onset were enrolled at a tertiary care centre. Patients experiencing no-reflow were categorized into Group A (primary PCI; n = 92) and Group B (pharmaco-invasive PCI; n = 192). Baseline demographics, comorbidities, angiographic characteristics, and outcomes were analysed. The primary outcome was the incidence of major adverse cardiac events at three months. Results: Among 857 patients undergoing primary PCI and 2,976 undergoing pharmaco-invasive PCI, the incidence of no-reflow was significantly higher in the primary PCI group (10.7% vs. 6.5%). Patients in Group A were older (58.9 ± 13.6 vs. 54.4 ± 11.4 years; P = 0.004) and more frequently diabetic (55.4% vs. 41.6%; P = 0.029), whereas hypertension was more prevalent in Group B (42.7% vs. 13.0%; P < 0.001). Baseline TIMI 0 flow was more common in Group A (79.3% vs. 24.5%; P < 0.001). After PCI, final TIMI 3 flow rates were comparable (85.9% vs. 89.6%; P = 0.361). In-hospital complications and three-month outcomes were similar between two groups: death (4.3% vs. 5.2%), revascularization (4.3% vs. 4.7%), and rehospitalization (5.4% vs. 3.1%) (all P > 0.05). Conclusion: No-reflow was more frequent after primary PCI, particularly in older, diabetic, and late-presenting patients with baseline TIMI 0 flow. Both reperfusion strategies achieved comparable short-term clinical outcomes in no-reflow patients. Pharmaco-invasive PCI may mitigate the risk of no-reflow in selected STEMI patients while maintaining equivalent early prognosis.
- Open Access
- 24 March 2026
- Published by Elsevier in International Journal of Cardiology Cardiovascular Risk and Prevention
- Vol. 29, 200624
Prognostic significance of carotid intima-media thickness in patients with coronary slow flow: A systematic review and meta-analysis
- 24 March 2026
- Published by Elsevier in International Journal of Cardiology Cardiovascular Risk and Prevention
- Vol. 29, 200624
Open AccessPrognostic significance of carotid intima-media thickness in patients with coronary slow flow: A systematic review and meta-analysis
- 2 July 2025
- Published by Elsevier in Heart Rhythm
- Vol. 22 (10) , e1000-e1006
Incidence and predictors of temporary pacemaker implantation–induced cardiac perforation
- 2 July 2025
- Published by Elsevier in Heart Rhythm
- Vol. 22 (10) , e1000-e1006
Incidence and predictors of temporary pacemaker implantation–induced cardiac perforation
- Open Access
- 21 January 2024
- Published by Springer Nature in Cureus
- Vol. 16 (1) , e52668
Reliability of Fractional Flow Reserve in Non-Infarct-Related Arteries in ST-Segment Elevation Myocardial Infarction Patients Undergoing a Pharmaco-Invasive Approach
Objectives We investigated the reproducibility of fractional flow reserve (FFR) of significant stenoses (>= 70% narrowing) in the non -infarct related artery (NIRA) during the pharmaco-invasive percutaneous coronary intervention (PCI) in patients with ST -segment elevation myocardial infarction (STEMI) within 24 hours of thrombolysis and at a follow up of 2-3 weeks. Background STEMI with multivessel disease has worse outcomes. The benefits of FFR-directed PCI of NIRA at the time of primary PCI are yet controversial. Assessing the hemodynamic severity of the NIRA may help in deciding the management strategy of these lesions, save time, and avoid complications. Methods Thirty-one patients undergoing PCI for STEMI under a pharmaco-invasive approach were prospectively recruited. The FFR measurements in 34 stenoses (>= 70% diameter stenosis) were obtained immediately after PCI of the culprit stenosis and were repeated at a mean follow-up of 17.6 +/- 3.55 (14-21) days. In addition, time to thrombolysis, time from symptom onset to PCI, left ventricular ejection fraction (LVEF), quantitative coronary angiographic measurements of the non -culprit stenoses, and thrombolysis in myocardial infarction (TIMI) flow were recorded. Results There was a significant change in FFR values at follow-up as compared to baseline (0.78 +/- 0.08 (0.68-0.93) to 0.77 +/- 0.08 (0.67-0.93)) (p = 0.014). In four of the lesions, the FFR values differed by >0.05 at follow-up. The follow-up FFR values led to a change in the management strategy in 5 out of 31 patients (15%) of the lesions. The TIMI flow, percentage diameter stenosis, minimum lumen diameter, and LVEF did not change. There were no predictors of this change in FFR values. Conclusions During the acute phase of STEMI, the severity of non -culprit coronary artery stenoses can not be reliably assessed by FFR. The prolonged jeopardized state of myocardium in pharmaco-invasive PCI as compared to primary PCI seems to be responsible.
- 21 January 2024
- Published by Springer Nature in Cureus
- Vol. 16 (1) , e52668
Open AccessReliability of Fractional Flow Reserve in Non-Infarct-Related Arteries in ST-Segment Elevation Myocardial Infarction Patients Undergoing a Pharmaco-Invasive Approach
Objectives We investigated the reproducibility of fractional flow reserve (FFR) of significant stenoses (>= 70% narrowing) in the non -infarct related artery (NIRA) during the pharmaco-invasive percutaneous coronary intervention (PCI) in patients with ST -segment elevation myocardial infarction (STEMI) within 24 hours of thrombolysis and at a follow up of 2-3 weeks. Background STEMI with multivessel disease has worse outcomes. The benefits of FFR-directed PCI of NIRA at the time of primary PCI are yet controversial. Assessing the hemodynamic severity of the NIRA may help in deciding the management strategy of these lesions, save time, and avoid complications. Methods Thirty-one patients undergoing PCI for STEMI under a pharmaco-invasive approach were prospectively recruited. The FFR measurements in 34 stenoses (>= 70% diameter stenosis) were obtained immediately after PCI of the culprit stenosis and were repeated at a mean follow-up of 17.6 +/- 3.55 (14-21) days. In addition, time to thrombolysis, time from symptom onset to PCI, left ventricular ejection fraction (LVEF), quantitative coronary angiographic measurements of the non -culprit stenoses, and thrombolysis in myocardial infarction (TIMI) flow were recorded. Results There was a significant change in FFR values at follow-up as compared to baseline (0.78 +/- 0.08 (0.68-0.93) to 0.77 +/- 0.08 (0.67-0.93)) (p = 0.014). In four of the lesions, the FFR values differed by >0.05 at follow-up. The follow-up FFR values led to a change in the management strategy in 5 out of 31 patients (15%) of the lesions. The TIMI flow, percentage diameter stenosis, minimum lumen diameter, and LVEF did not change. There were no predictors of this change in FFR values. Conclusions During the acute phase of STEMI, the severity of non -culprit coronary artery stenoses can not be reliably assessed by FFR. The prolonged jeopardized state of myocardium in pharmaco-invasive PCI as compared to primary PCI seems to be responsible.
- Open Access
- 20 September 2022
- Published by Elsevier in Indian Heart Journal
- Vol. 74 (5) , 357-362
Correlation of lipoprotein (a) levels and plaque morphology in very young acute coronary syndrome patients using optical coherence tomography
- 20 September 2022
- Published by Elsevier in Indian Heart Journal
- Vol. 74 (5) , 357-362
Open AccessCorrelation of lipoprotein (a) levels and plaque morphology in very young acute coronary syndrome patients using optical coherence tomography
- 14 February 2014
- Published by Springer Nature in International Journal of Hematology
- Vol. 99 (4) , 413-417
Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients
Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterised by isolated thrombocytopenia (peripheral blood platelet count 9/L) in the absence of other causes or disorders that may be associated with thrombocytopenia. The upfront treatment in newly diagnosed ITP patients is steroids; however, about one-third patients do not respond, and require other treatment, including IVIg, anti-D, or splenectomy. Previous studies have shown decreased platelet production in some ITP patients, aside from the evidence of enhanced platelet destruction. Thrombopoietin receptor agonists (TPO-RA), such as eltrombopag have been shown to provide good response in steroid non-responsive chronic ITP patients. We have studied response to eltrombopag in 25 newly diagnosed steroid non-responsive ITP patients; 80 % patients showed response at the end of 1 month, and 76 % sustained response at the end of 3 months. The platelet count rose from a mean value of 17.5 ± 3.6–152.5 ± 107.9 × 109/L at the end of 1 month. Our results suggest a possible role of eltrombopag in newly diagnosed steroid non-responsive ITP patients. However, our study is limited in that it is a single-centre study, with a small sample size, and lacks a long-term safety profile. Our findings highlight the potential value of a larger prospective study on the upfront use of TPO-RA in patients of ITP.
- 14 February 2014
- Published by Springer Nature in International Journal of Hematology
- Vol. 99 (4) , 413-417
Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients
Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterised by isolated thrombocytopenia (peripheral blood platelet count 9/L) in the absence of other causes or disorders that may be associated with thrombocytopenia. The upfront treatment in newly diagnosed ITP patients is steroids; however, about one-third patients do not respond, and require other treatment, including IVIg, anti-D, or splenectomy. Previous studies have shown decreased platelet production in some ITP patients, aside from the evidence of enhanced platelet destruction. Thrombopoietin receptor agonists (TPO-RA), such as eltrombopag have been shown to provide good response in steroid non-responsive chronic ITP patients. We have studied response to eltrombopag in 25 newly diagnosed steroid non-responsive ITP patients; 80 % patients showed response at the end of 1 month, and 76 % sustained response at the end of 3 months. The platelet count rose from a mean value of 17.5 ± 3.6–152.5 ± 107.9 × 109/L at the end of 1 month. Our results suggest a possible role of eltrombopag in newly diagnosed steroid non-responsive ITP patients. However, our study is limited in that it is a single-centre study, with a small sample size, and lacks a long-term safety profile. Our findings highlight the potential value of a larger prospective study on the upfront use of TPO-RA in patients of ITP.
- Open Access
- 30 January 2013
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 30 (S1) , 36-37
Pure Red Cell Aplasia: A Rare Complication of Isoniazid Therapy
- 30 January 2013
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 30 (S1) , 36-37
Open AccessPure Red Cell Aplasia: A Rare Complication of Isoniazid Therapy